
## Shu-Fu Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1858112/publications.pdf Version: 2024-02-01



SHILFH LIN

#	Article	IF	CITATIONS
1	Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural Mesothelioma. Human Gene Therapy, 2008, 19, 774-782.	2.7	67
2	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. Clinical Cancer Research, 2008, 14, 1519-1528.	7.0	57
3	Oncolytic Vaccinia Virotherapy of Anaplastic Thyroid Cancer <i>in Vivo</i> . Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4403-4407.	3.6	54
4	Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery, 2007, 142, 976-983.	1.9	46
5	Prognosis of Multifocal Papillary Thyroid Carcinoma. International Journal of Endocrinology, 2013, 2013, 1-6.	1.5	45
6	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy, 2016, 3, 15-30.	1.1	45
7	Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. Oncotarget, 2017, 8, 78429-78451.	1.8	45
8	Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1965-1970.	3.6	42
9	Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy. PLoS ONE, 2012, 7, e46726.	2.5	38
10	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE, 2017, 12, e0172315.	2.5	36
11	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. PLoS ONE, 2013, 8, e77684.	2.5	35
12	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Oncotarget, 2017, 8, 41294-41304.	1.8	33
13	MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. Cancer Letters, 2015, 369, 76-85.	7.2	29
14	1H Nuclear Magnetic Resonance (NMR)-Based Cerebrospinal Fluid and Plasma Metabolomic Analysis in Type 2 Diabetic Patients and Risk Prediction for Diabetic Microangiopathy. Journal of Clinical Medicine, 2019, 8, 874.	2.4	27
15	Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastasis. PLoS ONE, 2017, 12, e0173354.	2.5	23
16	Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer. Pediatric Surgery International, 2012, 28, 489-494.	1.4	16
17	Activity of roniciclib in medullary thyroid cancer. Oncotarget, 2018, 9, 28030-28041.	1.8	16
18	Maternal and fetal outcomes of pregnant women with type 1 diabetes, a national population study. Oncotarget, 2017, 8, 80679-80687.	1.8	15

Sни-Fu Lin

#	Article	IF	CITATIONS
19	Epithelial–Mesenchymal Transition Enhances Response to Oncolytic Herpesviral Therapy Through Nectin-1. Human Gene Therapy, 2014, 25, 539-551.	2.7	14
20	The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. Nuclear Medicine Communications, 2018, 39, 1091-1096.	1.1	14
21	Sensitivity of Squamous Cell Carcinoma Lymph Node Metastases to Herpes Oncolytic Therapy. Clinical Cancer Research, 2008, 14, 1897-1904.	7.0	12
22	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocrine-Related Cancer, 2018, 25, 853-864.	3.1	9
23	Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2521-e2530.	3.6	8
24	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Endocrine-Related Cancer, 2019, 26, 727-738.	3.1	8
25	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget, 2017, 8, 67990-68000.	1.8	8
26	Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. World Journal of Clinical Cases, 2021, 9, 71-80.	0.8	4
27	Efficacy of adavosertib therapy against anaplastic thyroid cancer. Endocrine-Related Cancer, 2021, 28, 311-324.	3.1	4
28	Therapeutic inhibition of poloâ€like kinases in anaplastic thyroid cancer. Cancer Science, 2021, 112, 803-814.	3.9	4
29	Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Case–Control Cohort Study. Cancers, 2021, 13, 3955.	3.7	3
30	Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. Cancers, 2021, 13, 3487.	3.7	2
31	Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas. International Surgery, 2019, 104, 304-313.	0.1	0